Team
Our Founders
Move at the Speed of Experience™
Christina J. Ansted, MPH, CCMEP
Co-Founder and CEO
Christina is a multifaceted biotech executive with expertise in global commercialization, medical communications and rare disease. Adept at building high-performance teams that drive value across an organization, Christina is deeply inspired to create a legacy of innovation by changing the approach to commercialization, improving rates of success and impacting the lives of patients worldwide.
Michael C. Janes
Co-Founder and CRO
Head, Private Market Practice
Michael has led global teams focused on global business development, private equity, sales operations, training and development, and business process optimization. With a commitment to outcomes and outstanding relationship management, Michael’s vision is to drive value creation for private market clients with biotech centric portfolios.
Executive Team
Levarage a Commercial Catalyst - Multidisciplinary Experts to Support Value Creation Opportunities
Andy Parratt
Head, Commercial Strategy & Execution
Andy has deep commercialization expertise across a wide range of therapeutic areas and organizations ensuring that scientific innovations reach and benefit patients. He brings an integrated approach for early commercial planning encompassing R&D, market access, pricing, MR and analytics to drive the development and commercialization of assets in areas of high unmet need across US, European and global markets. Solution oriented, Andy combines operational agility with strategic focus to address meaningful challenges in healthcare.
Natalie Rettinger
ED, Commercial Strategy & Planning
Natalie has over 15 years of commercialization experience, primarily in hematology/oncology with a proven track record of managing key in-line and pipeline products. A commercial thought leader with an entrepreneurial spirit, Natalie has led lifecycle management, commercial assessments and launch planning for oncology programs for mid-size global biotech and life science companies. She is also an independent product strategist in Health IT working to improve/innovate the care and communication for cancer patients.
Paresh Soni, MD, PhD
Head, Clinical and Corporate Development
Paresh is a board-certified internist and gastroenterologist with hepatology expertise and broad medical/scientific and corporate management experience having led clinical development programs, and global multidisciplinary teams across the development spectrum, with a proven record of multiple successful NDAs.
Barry Marston
SVP, MedTech Ventures
Barry is a senior level medical device executive with demonstrated leadership in medical device commercialization, sales and marketing strategy, business and product development, strategic analysis and growth planning and oversees all RCP medical device engagements. Barry also serves as mentor with Rockies Venture Club for medical device entrepreneurs.
Kate Worthington, PhD, MBA
Chief Operating Officer
Kate is a multidisciplinary executive with expertise in medical affairs, M&A and commercialization whose skills converge at the intersection of drug development, physician research, and data sharing. Internationally recognized for her expertise in oncology, Kate is focused on getting better medicines to patients faster and cheaper by promoting bi-directional scientific exchange and compressing time to market.
Sean McElduff
Chief Financial Officer
Sean is an experienced finance and operational professional with exceptional expertise in accounting, pre-IPO preparedness, diligence for M&A opportunities, venture equity, FP&A, GAAP financials, and board reporting. He serves as an interim and fractional chief financial officer and finance subject matter expert providing finance operational support and guidance for start-up and clinical stage clients to ensure launch readiness and scalable growth.
Daniel Silver, Esq.
Chief of Staff
Dan, an attorney by training, brings his legal expertise and experience as a biotech coordinator to support daily operations of the leadership and executive teams, executive corporate administrative functions, vendor and partner relations and strategic implementation.
Kevin W. Mayo, PhD, EJD
SVP, Global Market Access & Health Economics
Kevin’s extensive expertise in market access, pricing and reimbursement, HEOR, health policy and government affairs, and patient /medical advocacy enables him to maximize global revenue potential and market share growth. He leads patient and market access strategy and implementation.
Joseph Rubino
ED, Reimbursement and Market Access Strategy
Joseph is a veteran market access, reimbursement and government affairs expert with interests in diagnostic and medical device strategy, HEOR and payer/provider market research. He leads projects focused on coding, coverage, payment, evidence generation, launch plans and value communication strategies.
Jennifer King, MBA
VP, Global Pricing & Payer Insights
Jennifer brings a wealth of commercial and market access experience across oncology and orphan drugs. She is well-versed in global, EMEA and Asia Pacific/Japan markets supporting pricing and market access strategies in both strategic development and implementation with the goal of achieving optimal access for all stakeholders.
Andy S. Verderame, MBA, RAC
Chief Regulatory Officer
Andy interacts on behalf of clients working with the US FDA. He has been an active and highly respected member of the regulatory community for decades and has personally led over 100 meetings with the FDA, managed multi-site global regulatory teams for both large and small pharma, and led preparations and presentations to FDA Advisory Committees with successful outcomes. Of note, Andy was the first industry representative invited to speak at the FDA Project Manager Forum.
Art Vrecenak, PhD, MBA
ED, Managed Markets Access
Principal at Access Acumen, Art has broad experience across field sales, health economics, product management, clinical development, hospital/GPO marketing, national HMO marketing, national PBM marketing, strategic customer marketing, and generic product business strategy. He has developed and led teams tasked with value proposition development and communication for both pharma benefit and medical benefit products. This depth and breadth of experience feeds a passion for optimizing product performance throughout the product life.
Ramin Pourfarzib, PhD
Head, Field-Based Medical Affairs
Ray has led medical, clinical affairs and medical scientific liaison teams. He provides strategic support for national advisory boards and speaker development programs as well as medical and scientific training and management of field-based scientific resources. Experienced in the implementation of clinical research studies and publications, Ray also assists with thought leader and investigator relationship management.
Tom Lo, PhD
Head, Clinical Sciences & Diagnostic Strategy
Tom has exceptional experience expanding the treatable patient population for therapeutics. With a focus on building awareness for diagnostic testing to enable optimal patient identification and timely therapy, Tom has led diagnostic strategy for eight rare diseases and provided leadership to develop and implement diagnostic strategy supporting field implementation and training across a myriad of therapeutic areas. He applies his considerable field sales acumen to ensure successful collaboration, integration, and execution of strategic diagnostic initiatives.
Strategic Advisors
Victoria Danilchouk
International Expansion, Commercialization Strategy and Digital Health
Based in Brussels, Belgium, Victoria is an industry veteran and senior advisor with expertise in commercial strategy, product management and market access. She specializes in new product strategy, commercialization, pricing, reimbursement, partnerships, with a special focus on global expansion and commercialization strategies for Europe, LATAM, MENA and APAC. Founder of Pretium Strategy, Victoria’s proficiency spans multiple therapeutic areas across both medicines and medical devices, including digital health solutions and digital therapeutics.
Edward Dow, MD
Global Medical Affairs
Principal at ValueGenome, Edward is a highly experienced physician executive and practicing Hematologist-Oncologist with more than twenty-years of immuno-oncology and hematology clinical expertise combined with an extensive knowledge of global medical affairs and clinical development. Providing data generation and synthesis for medical support of new product commercialization, Ed brings global launch experience in rare blood disorders driving successful collaboration between clinical development and regulatory colleagues. Ed continues to see patients with cancer and blood diseases on a part-time basis in the community setting.
Safia Rizvi, PhD
Early Commercial Development
CEO of CILA Therapeutics, Safia is a life science business executive and entrepreneur with more than 20 years of experience in all aspects of the biotech/pharma value chain, from discovery to commercialization. A former computational biologist with a deep understanding of AI data, informatics, clinical trials and market access, she is highly skilled at transitioning scientific concepts into product pipelines and has served as a strategic advisory for biopharma CEOs and leadership teams.
Kelly DeAngelis
Public Relations & Communications
Founder and President at Pilcrow Group, Kelly is an award-winning communications and public relations leader with extensive experience creating and executing strategic
communications plans that drive engagement and visibility. She has a proven track record of building and leading high-performing teams and is passionate about helping companies tell their stories.
Chris Roebuck
Health Economics & Policy
Founder and CEO of RxEconomics, Christopher is a veteran health economist with extensive health economics outcomes research (HEOR) experience. He has considerable expertise in employing advanced econometric methods in observational research studies using insurance claims data and brings a high degree of proficiency to developing predictive models, conducting economic evaluations of health care programs, and examining issues of health plan choice. Chris’s work has also been published in several premier economic journals.
Stephen F. Amato, PhD, MBA
Global Regulatory Affairs
Steve is a global regulatory affairs expert with vast experience in the healthcare sector. With a strategically oriented, collaborative and evidence-based approach, he has worked directly with the FDA and developed strategies for medical device and biopharmaceutical products. Steve is principal advisor and chief strategist at tJûn17 Life Science Advisors and serves as Department Chair and Professor of Regulatory Affairs and Quality Assurance at Northeastern University College of Professional Studies.
Greg Fuest
Global Commercialization Strategy
Greg is an exceptional marketing and commercial strategy executive with extensive experience in large pharma and startup biotech companies leading cross-functional teams for pre-launch, launch, re-launch and in-market brands in primary care, oncology, virology, respiratory, ERT, gene therapy and rare disease, globally and in the U.S., in addition to notable divisional/regional sales management expertise.